Organ-Sparing Strategies in Muscle-Invasive Bladder Cancer
Authors:
- J Alfred WitjesJWJ Alfred Witjes
- Astrid Ah FeikemaAFAstrid Ah Feikema
Open Access
- 1 October 2021
- journal article
- review article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 13, 7833-7839
Abstract
Radical cystectomy (RC) is the treatment of choice and is strongly recommended for patients with pT2-4aN0M0 bladder cancer in both the European Association of Urology (EAU) and American Urological Association (AUA) muscle-invasive bladder cancer (MIBC) guidelines. RC is a challenging operation, with significant perioperative and postoperative morbidity and mortality, having short-term complication rates between 14.4% and 21.7%, and long-term oncological survival rates ranging from 60% after 5 years to 43% after 10 years. The impact on quality of life (QoL) in patients after treatment for bladder cancer is significantly worse than in other pelvic cancers. Although RC is strongly recommended as the gold standard, there is a need for bladder-sparing options in MIBC. Attempts to improve mortality and morbidity rates after RC have been made by implementing Enhanced Recovery After Surgery (ERAS), robot-assisted RC, and sexual function-preserving techniques. None of these significantly improves QoL or functional outcome. Because of the invasiveness of RC, other therapeutic options have been evaluated. Transurethral resection of the bladder tumor (TURB) plays an important role in the diagnostic evaluation of MIBC and has also been reviewed as a curative option, although the oncological results appear inferior to RC. Furthermore, improved radiotherapy (RT) and widely used chemotherapy, both as monotherapeutic options in bladder cancer, are not as effective as radical surgery, with lower survival rates. Trimodality treatment (TMT) in bladder cancer combines TURB with chemotherapy and RT. The goal of TMT is preserving the bladder and QoL without compromising oncological outcome. A 2018 review showed no difference in overall survival rates between RC and TMT (30.9% vs 35.1%), with lower survival rates after RC than TMT in the first year of follow-up, probably due to higher postoperative mortality. For a selected group of patients, TMT is to be recommended, and it is the most favorable option out of the organ-sparing strategies in MIBC.Keywords
This publication has 25 references indexed in Scilit:
- Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical TreatmentInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Systematic review of the oncological and functional outcomes of pelvic organ‐preserving radical cystectomy ( RC ) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancerBJU International, 2017
- Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO GuidelineJournal of Urology, 2016
- 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based studyThe Lancet, 2015
- Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS®) society recommendationsClinical Nutrition, 2013
- Does Partial Cystectomy Compromise Oncologic Outcomes for Patients with Bladder Cancer Compared to Radical Cystectomy? A Matched Case-Control AnalysisJournal of Urology, 2012
- 25 Years of Experience With 1,000 Neobladders: Long-Term ComplicationsJournal of Urology, 2011
- Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experienceBJU International, 2010
- Feasibility of Radical Transurethral Resection as Monotherapy for Selected Patients With Muscle Invasive Bladder CancerJournal of Urology, 2010
- Transurethral Resection of Muscle-Invasive Bladder Cancer: 10-Year OutcomeJournal of Clinical Oncology, 2001